Nicholas Valiante

Nicholas Valiante is a highly accomplished scientist and industry leader in the field of vaccine development and immunology. He is currently the Co-Founder, Chief Scientific Officer (CSO), and President of Innovac Therapeutics, a biotechnology company focused on developing innovative vaccines using proprietary RNA technology platforms.13

Career Highlights

Dr. Valiante has an extensive background in vaccine design, development, and clinical testing. His career spans several prominent pharmaceutical and biotech companies:

• Innovac Therapeutics: Co-Founder & CSO (March 2022 - Present)2
• Glyde Bio, Inc.: Founder and CEO (November 2018 - October 2022)2
• Moderna Therapeutics: Head of Research at Caperna LLC, a Moderna venture (September 2015 - December 2017)2
• GSK: Global Head of Immunology and Immunotherapy (March 2015 - September 2015)2
• Novartis Vaccines: Various leadership roles, including Global Head of Immunology and Immunotherapy (2007 - 2015)2
• Chiron Corporation: Multiple positions, including Director of Immunology and Global Head of Adjuvant Discovery (1998 - 2006)2

Expertise and Contributions

Dr. Valiante is recognized as a vaccine industry thought leader with deep experience in all aspects of vaccine development. He has:

• Advanced vaccines and therapeutics targeting infectious diseases, cancer, allergy, autoimmunity, and aging1
• Led clinically successful scientific and technical teams across various vaccine and biopharma platforms1
• Pioneered mRNA technologies as vaccines and therapeutics1
• Developed a best-in-class Personalized Cancer Vaccine (PCV) platform at Moderna in just two years1

Education

• PhD in Immunology from the University of Pennsylvania12
• BA in Evolutionary Biology from Boston University12
• Post-graduate training at Stanford University1

Dr. Valiante's extensive experience and expertise in vaccine development, particularly in mRNA technologies, make him a valuable asset to Innovac Therapeutics as they work on developing innovative vaccines for unmet medical needs.